Emerging drugs for schizophrenia: an update
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Schizophrenia is one of the most serious mental disorders. Its treatment remains challenging, as existing antipsychotic antidopaminergic medications improve only/predominantly positive symptoms, agitation and aggression but have limited/insignificant efficacy for negative and cognitive symptoms, which strongly affect functional outcome. Therefore, new therapeutic agents are urgently needed that treat aspects of the spectrum of schizophrenia symptomatology and improve functional outcome. AREAS COVERED: The authors review the mechanisms of action and key clinical results of drug development targets currently in Phase II and III clinical testing for schizophrenia. They further discuss potential barriers to the successful development of these targets and summarize the drug development status of emerging treatments for various aspects of schizophrenia. EXPERT OPINION: Although modifications and variations of antidopaminergic mechanisms are expected to be successful, the added benefits will likely remain small, at least regarding enhanced efficacy for negative symptoms, cognition and functional outcomes. Greater innovation will likely come from further and deeper exploration of extra-dopaminergic mechanisms. Investment is needed to develop clinically meaningful animal paradigms probing the different symptom domains, to discover more efficient in vivo screening methods for novel drug targets, to optimize clinical trial design and trial conduct, and to parse the heterogeneous groups of schizophrenias into biologically more homogeneous subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Salomon, J. A., Vos, T., Hogan, D. R., Gagnon, M., Naghavi, M., Mokdad, A., Begum, N., Shah, R., Karyana, M., Kosen, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61680-8 · Cited by 1,322
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 1×
“Further, safety and tolerability concerns regarding weight gain and metabolic side effects have risen that are more common with most SGAs and that can increase physical illness burden and shorten life expectancy [15,16].”
BackgroundCannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059 · cited 1×
“Cannabidiol was well tolerated and clinical improvement correlated significantly with increased serum anandamide levels [75].”
BackgroundIncreased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558 · cited 1×
“Additionally, off-label prescribing for aggression associated with disruptive behavior disorders or dementia, obsessive compulsive disorder, anxiety disorders, post-traumatic stress disorder and insomnia [80] further increased sales of agents developed originally as antipsychotics for schizophrenia.”
BackgroundCarbamazepine for schizophrenia
Leucht, S., Helfer, B., Dold, M., Kissling, W., & McGrath, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001258.pub3 · Cited by 82 · cited 1×
“Augmentation strategies for positive symptoms have involved pro-glutamatergic agents, valproic acid [23], carbamazepine [24], lithium [25], lamotrigine [26], benzodiazepines [27], b blockers [28] and agents with anti-inflammatory properties [29,30].”
BackgroundLaffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0132-7 · Cited by 35
Cited by
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Self-citationStubbs, B., Vancampfort, D., Hallgren, M., Firth, J., Veronese, N., Solmi, M., Brand, S., Cordes, J., Malchow, B., Gerber, M., et al. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.07.004 · Cited by 697
Self-citationWeight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
Manu, P., Dima, L., Shulman, M., Vancampfort, D., De Hert, M., & Correll, C. U. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12445 · Cited by 285
Self-citationThe acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
Haddad, P. M., & Correll, C. U. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318781475 · Cited by 259
Self-citationCarbon, M., & Correll, C. U. (2014) · CNS Spectrums · doi:10.1017/s1092852914000601 · Cited by 258
Self-citation
Metadata
- Authors
- Köster, L.-S., Carbon, M., & Correll, C. U.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2014-09-19
- Volume
- 19
- Issue
- 4
- Pages
- 511-531
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2003154946
- Cited by
- 52
- References
- 10
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging drugs for schizophrenia: an update. https://app.cochat.ai/papers/10.1517/14728214.2014.958148
- The paper
- Köster, L.-S., Carbon, M., & Correll, C. U. (2014). Emerging drugs for schizophrenia: an update. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.2014.958148
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.